Study of new drugs for advanced prostate cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older.
- You have prostate cancer that has spread to other parts of the body (metastatic).
- You have had surgical or medical castration to lower testosterone levels.
- Your cancer has gotten worse despite treatment (for some parts of the study).
- You have not taken certain previous treatments like abiraterone, enzalutamide, or B7H3-targeted therapies.
- You do not have cancer that has spread to the brain or spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new oral drug called XNW5004 in combination with other standard treatments (like abiraterone, enzalutamide, or chemotherapy) for advanced prostate cancer that has spread and is no longer controlled by hormone therapy alone. The goal is to see if these combinations work better than current options.
This trial tests a new drug called QLH12016 combined with a hormonal therapy for men with advanced prostate cancer that has spread. It aims to see if the combination is safe and effective.
This trial tests QLC5508, a new targeted drug for men with metastatic castration-resistant prostate cancer (advanced prostate cancer that has spread and stopped responding to hormone therapy). The drug is designed to work in patients whose cancer has progressed despite prior hormone-based treatments.
This early-stage trial tests a new drug (QLF4113) designed to help the immune system fight metastatic castration-resistant prostate cancer—a type that has spread and stopped responding to standard hormone therapy. You may qualify if you've already tried other treatments and your overall health is stable enough for the study.
This trial tests a new drug (TYK-00540) combined with enzalutamide for men whose prostate cancer has spread and is no longer responding to standard hormone therapy. It may be an option if you have tried only one other newer hormone treatment and it failed.
This trial tests a new radioactive drug (177Lu-TLX591) plus standard care against standard care alone for men with metastatic castration-resistant prostate cancer that has progressed on an androgen receptor pathway inhibitor. The goal is to see if this targeted radiation can help control the cancer.
Hear when a new Advanced Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.